Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 158

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 158
---
 to time, of up to an aggregate of 37,625,790 shares of our Common Stock, including 6,372,265 shares of Common Stock issuable upon exercise of Investor Warrants. by the Selling Stockholders identified in this Resale Prospectus under the caption “Selling Stockholders.” We are not selling any shares of our Common Stock under this Resale Prospectus, and we will not receive any proceeds from the sale of Shares of Common Stock offered hereby by the Selling Stockholders, although we may receive $7,413,436 from the exercise of the outstanding Investor Warrants, if they are exercised for cash.

Investing in our securities involves a high degree of risk. See “Risk Factors ” beginning on page 5 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus is _______________, 2025.

TABLE OF CONTENTS</div>

|                         |     | Page   |
| About This Prospectus   |     | Alt-ii |
| Summary of the Offering |     | Alt-1  |
| Selling Stockholders    |     | Alt-2  |
| Use of Proceeds         |     | Alt-4  |
| Plan of Distribution    |     | Alt-5  |

<div align='center'>Alt-i

[RESALE PROSPECTUS ALTERNATE PAGE]

ABOUT THIS PROSPECTUS</div>

This Resale Prospectus is part of a registration statement on Form S-1 that we filed with the U.S. Securities and Exchange Commission (the “SEC”). You should read this prospectus and the information and documents incorporated herein by reference carefully. Such documents contain important information you should consider when making your investment decision. This Resale Prospectus is related to the resale by the Selling Stockholders identified in this Prospectus under the caption “Selling Stockholders,” from time to time, of up to an aggregate of to 37,625,790 Shares of our Common Stock, including 6,372,265 shares of Common Stock issuable upon exercise of Investor warrants. We are not selling any shares of our Common Stock under this Prospectus, and we will not receive any proceeds from the sale of Shares of Common Stock offered hereby by the